In short
Podcast Notes: CNBC's "Fast Money"
Episode Title
Semi Stocks Get Smacked, and Roche Ups the Ante in the Weight Loss Drug Battle
Date
7/17/24
---
Episode Overview In this episode, hosted by Melissa Lee with a panel of expert traders, the discussion revolves around the significant downturn in semiconductor stocks and the impact of Roche's new weight-loss drug trial results on the pharmaceutical market.
---
Key Topics
- Semiconductor Stocks Decline
- Market Movement: Semiconductor ETF (SMH) experiences its worst day in over four years, dropping by 7%.
- Key Players Affected:
- ASML: Significant decline noted, leading to broader sector concerns.
- Taiwan Semiconductor: Down nearly 8%.
- Nvidia: Discussion on potential price targets down to the $102-$105 range.
- Geopolitical Concerns:
- Rising tensions between the U.S. and China, particularly regarding Taiwan.
- Comments from President Biden and former President Trump emphasizing potential escalations in trade tensions leading up to elections.
Discussion Points
- The traders debated whether this decline signals the end of a bullish trend for semiconductors or is merely a market correction.
- Potential for continued volatility due to political rhetoric and geopolitical concerns affecting trade.
- Roche's Weight Loss Drug Trials
- Positive Results: Roche's oral GLP-1 weight-loss drug shows promising results in early trials, with participants losing significant body weight compared to a placebo group.
- Market Reactions:
- Roche's stock rises 7.5%.
- Competitors like Eli Lilly and Novo Nordisk see their shares drop by nearly 4%.
- Market Implications: The potential for Roche to disrupt the market dominated by established players raises concerns about competition and market dynamics.
Expert Insights
- Discussion on the implications of Roche's results and whether these could lead to a broader competition in the weight loss pharmaceutical market.
- Consideration of Roche's recent acquisition of a company developing this drug and the significance of further trials.
- Broader Market Trends
- Copper Miners: Noting a decline in copper prices and its impact on mining stocks, signaling possible economic slowdown.
- Earnings Reports:
- United Airlines beats earnings expectations but gives a cautious outlook.
- Discover Financial shows strong earnings but also faces scrutiny over consumer credit trends.
Key Insights
- Analysts stress the importance of focusing on earnings quality over mere stock performance, especially in smaller cap stocks.
- The discussions also touched upon the dynamic nature of the market with unusual movements in sectors like energy and healthcare in light of recent economic data.
---
Key Takeaways
- Semiconductor Sector: Traders are cautious about the semiconductor sector's future due to political tensions and market corrections. The consensus suggests a fundamental reason for the sell-off, not just a market reaction.
- Pharmaceutical Market: Roche's trial results could signal a competitive shift in the weight loss drug market, but concerns over statistical significance and future developments remain pertinent.
- Market Dynamics: Volatility across various sectors suggests a complex interplay of factors influencing investor sentiment, highlighting the need for careful analysis in earnings reports and market positions.
---
Conclusion The episode provides a comprehensive overview of significant market movements in technology and healthcare, underlining the importance of geopolitical factors and market fundamentals in investment decisions. The panel's insights reflect a blend of caution and optimism as they navigate the complexities of the current trading environment.
---
Additional Notes
- Final Trades: Panelists suggest a mix of stocks for consideration based on current market conditions, emphasizing a tactical approach to investing.
- Next Episode Focus: Anticipation for Netflix’s earnings report and potential market impact based on options trading behavior.
---
For more information, visit [Fast Money’s website](http://fastmoney.cnbc.com).
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:02Live from the Nasdaq market site in the heart of New York City's Times Square. This is Fast money. Here's what's on tap tonight. A chip wreck. ASML and Taiwan Semi leading the sector to its worst day in more than four years. Is this a sign of continued rotation or a reason for more concerns for the group? We'll debate that. And rocketing roach. Shares of the Swiss pharma giant touching highs not seen in over a year thanks to positive results for its weight loss pill. The impact it's having on the other big players in the space. Plus, copper miners lose their shine. United Airlines on the move after results.
0:33And we're counting down to Netflix earnings as a streamer tries to reclaim all-time highs. I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Karen Feinerman, Dan Nathan, and Guy Adami. And we start off with the chip stocks getting hammered. The VanEck Semiconductor ETF plunging 7 % today, its worst day since the start of the pandemic. ASML, applied materials, and advanced microdevices all down double digits. Taiwan Semi also among the laggards down almost 8 percent. The latest moves coming as comments from both President Biden and former President Trump indicate that trade tensions with China will, in fact, ramp up going into the elections here.
1:11So this is coming from all sides in terms of political parties, and that is having the impact on the chip sector. Trump specifically questioning whether the U.S. would actually defend Taiwan in the event of a Chinese attack. So really throwing some concern on this trade. The chip sell-off driving the NASDAQ to its worst one-day loss in September, December, I should say, 2022. The tech-heavy index dropping almost 3%. So does today's action mark the end of the red-hot semi-trade, no matter what the outcome of this election? Guy, what do you say? The end. Well, last night CQ was here. You were on a shoot, as they say.
1:45You were on assignments. You were on assignments. That's your want to be. And it broke during our show. And, you know, a couple things struck me, the comments about Jerome Powell and about the Fed cutting rates this year. But the Taiwan comments really, to me, were market moving. And I was surprised the market didn't move in the aftermath when we were on the show. With that said, you know, as much as people want to say a Trump presidency is bullish for the market, maybe it is. It's bearish for technology. And I think you're starting to see it on the edges today. So I think the seeds were sown again on June 20th when we saw that reversal, not unlike what we saw in early March.
2:18And I think it's going to continue for the foreseeable future. I mean, there's a chance that a name like NVIDIA can trade down to sort of between 102 and 105, which is not ridiculous given this move we saw back in mid-April or so. I mean, chips at this point are really stuck between a rock and a hard place, so to speak, in terms of Biden saying, you know, our allies should tighten export controls in terms of what we export, what kinds of technology are exported. And then Trump saying about Taiwan, they took our chip business. I mean, either way, it's not good in terms of the rhetoric. Yeah, so you can focus on the fundamentals.
2:49So you can focus on the visibility that these companies have if we have tighter trade policy. Right. And so, again, nobody knows what's going to happen there. But I just say this, if you look at some of these companies that have massively outperformed, at least their stocks have. I mean, think about an ASML. They gave an outlook last night that wasn't as good as, let's say, some very optimistic people thought. That coupled with the geopolitical outlook, it makes for a difficult situation. Then you think about Taiwan Semiconductors. So ASML makes the machines that go into a fab that Taiwan Semiconductor has, and they have 85 % of the high-end GPUs.
3:25Then you can draw a line to NVIDIA. And then you can start thinking about what all these hyperscalers and all these companies that are basically building servers to go into data centers that are basically going to service all these companies. And to me, I think we're probably ready to have a little bit of slowdown as far as the demand is there. We've had tens of billions of dollars of spend over the last year and a half or so. Until these companies start seeing what the ROI might look like, you might see a little bit of a slowdown. So to me, I think there is fundamental reasons why the stock sold off.
3:58I think people were looking for an excuse to sell. And then obviously the visibility issue. Does the whole notion that everybody's going to spend on AI, that AI is the next coming of the Internet, does that change based on these headlines, though? I don't think so. So why should there be this sort of, I mean, as long as the hyperscalers are going to spend because they have to invest, NVIDIA should still have its business. So what's the issue? So the issue would be, I think, if the correlation exactly matched where we were and where we, I think, where we still are. But I think it's quite possible that it was ahead of where we are.
4:31I think the train has left the station. The AI spend will come. It just does. I don't know exactly when all of it will come. But, you know, it's so whenever things sort of get overheated, like, you know, this sector does. And I'm long. I am. You know, today was just not a great day at all. But you know that this could come right. This sort of reversal when you have something that goes up like this. So I think, you know, we can point to things. I think the comments about Taiwan, it wouldn't be shocking three days later to see a different comment about Taiwan. Right. That could absolutely happen.
5:04But I think, you know, the Tinder was kind of there just ready for the match. And so, you know, we saw ASML, as you said, it was a thousand euros two days, three days ago. I don't know. Or last week. So I think this story is still intact. I'd really like to get, though, we're starting we're going to start to get earnings and we'll see. We'll see what Microsoft Cloud looks like. We'll see what by the end of July. We'll see Amazon. We'll see Google. We won't see NVIDIA. as we talked the other night until end of August. But I think if we could get back to what are they actually earning and away from what's all the macro, then we'll have a little more clarity.
5:42I don't think it's about the semi trade being dead. I think it's about the world that we've had in the last week. And so it goes all the way back to that CPI, which was a week ago. Since that point, we've seen extraordinary outperformance by small caps, equal weighted S &P value. I mean, pick your places that are the real economy. The Dow Jones was up for the sixth straight day and another straight record on a day. I mean, it outperformed the S &P substantially. Equal weighted outperforms by 2 percent today. So so those are the things that I would be more focused on. I would be focused on macro and positioning.
6:12And obviously, we've had a whole lot of macro and we've had a whole lot of positioning building up to this point. I don't think the fundamentals really change. I think the fundamentals were always to be challenged in terms of what do I want to pay for these companies? But the fact that the VIX is now, you know, starting to make a move, we probably thought we were going to walk in on Monday and see a VIX significantly higher than we did. I think the dynamics Dan brings up around ASML, I mean, their orders actually thought they were quite strong. But this is a name that also very, very crowded. Remember, this is like Europe's chip play.
6:41So if you're investing in Europe and I've got an international ETF, we've loved ASML because, in fact, it's a way to get that kind of exposure. I think this is a case of where, hey, look, there's no question Biden or Trump is going to say, don't circumvent our restrictions on China and China technology. And this goes all the way back to Huawei. So this is stuff that I think the market's now paying attention to. I felt like today was a healthy day in the markets. I mean, it was a day where we've kind of put an exclamation point on a broadening of the market. And there was stuff the banks enjoyed today.
7:13I mean, we're getting good earnings out of certain parts of the sector. That was my focus. ASML, I didn't realize, is Europe's largest tech company. It's that big. But going back to the CPI print, it also coincided with the timing approximately of when Trump's odds in the betting markets went up. And I ask this question not because I want to say it's because of President Trump that we're having this rally, but to understand what the foundation of this rally is. Because if the Trump trade, so to speak, is driven by political wins, then what we're seeing in terms of the advances that we've seen over the past week could just as easily go the other way.
7:47So what is it? Is it that we know that the Fed, with 100 percent certainty, according to Fed Funds Futures, is going to raise, cut interest rates by 25 basis points in September? Or is it the Trump trade? Yeah, I think that, you know, and you know the answer to those questions are typically some, you know, some sort of mixture of the two. But yet to answer it, I think, specifically, the Fed is, to me, still the most important thing. But I think the catalyst for it is now on the back of the odds of another Trump presidency. I think that's sort of taken over for the Fed, which all makes sense. But I'll say this as well.
8:21You know, there are a lot of things happening. You would think that a president, new President Trump, would be bullish for energy. You know, I talked to Liz Ann Saunders earlier today. She's going to be on the show. Somewhat counterintuitive is actually the Biden administration that was best for the energy sector. But in terms of banks, and I think all three of us would agree, and Mel, you would as well, You know, the point, the potential for deregulation and less restrictive policy under a different administration would be extraordinarily healthy. And I think to a large extent, that's what the banks are rallying on.
8:50Yeah. So going back to the fundamentals and the chip trade, I just want to make one point. I saw something strange today, Guy, and it was an article in the information. That's why I stopped for a second. So you see what he just did there? He tried to do it very. He rushed it a little bit, but he was doing a little godfather, too. He was doing a little Michael Corleone sitting out on the terrace in Cuba. And he said, I saw something strange today. But I thought he just saw something strange. I know what he was trying to feel like because he's not a tiny can't really even deliver. I do. I actually.
9:17Yes. And you're right to sense that. But please. But you just did an Ocean's Eleven. You rushed it. I said you did there. All right. Really quickly. OK. There was an article in the information. Maybe it wasn't that strange. But bringing it back to use cases, they had an interview with Chevron. That's one of your big oil companies last summer with the CIO, the chief investment officer. Last summer, they created an enterprise AI group, okay, tasked with creating some large language models that will make their employees, make certain processes within their busy business more productive, make some of the employees more productive.
9:50And what he said in the interview was that the jury's still out here. They've gone through some of these applications. They've done a spend. They're training some other stuff on Microsoft's CoPilot, but he's not convinced yet. That sort of commentary will take air out of this trade. I think we're going to be anniversary-ing on two years this fall of the release of ChatGPT, okay? And I just think that if we can't find the use cases in the enterprise, I think you're going to see some of the spend slow down. I think there's a lot of people who say they are finding use cases. If you hear like Jamie Dimon talk about banks and all of the opportunities that they see, I think that there is that use case.
10:27I don't think that the reason is that. I think they were just kind of overdone. And I don't think that we're going. Well, let's say actually, let's wait. Let's see what Meta has to say, because we did see them both do a lot of spend and also improve their business a lot. Right. Because of it. Because of it. So that was really important. So I'd like to see the continuation of that. And that would allow people to say, all right, well, OK, we're with you on the spend. All right. For more on today's market action and where we could be headed next, let's bring in Lizanne Saunders of Charles Schwab.
11:00Lizanne, welcome to FAST. Nice to be here and nice to see you guys. Where are we in this rotation? Is this for real? I think to some degree it's for real, assuming the expectations around the shift in Fed policy at the September meeting come to fruition. That's it. I think the extreme outperformance that we've seen by smaller cap stocks by the Russell 2000 is not likely to persist at that same pace. I see it more as we're likely to get bouts of this type of action where you get some profit taking up the cap spectrum. And there is money looking for opportunities down the cap spectrum. But I wouldn't I wouldn't expect it to persist to the degree it has in the past week, week and a half.
11:39Is it not wise at this point? I mean, a 10 percent run or so over the past week in small caps. I mean, we have to also think that the small cap index is not made up of the most vibrant companies. Some of them are fallen angels that just have declined in value. so much. They've gotten into the small cap index. How should we approach thinking about small caps at this point? Well, don't approach it monolithically, because I think that's a real danger. Small caps is a big category. Even the Russell 2000 index has, even though it doesn't have 2 ,000 stocks, it's got 1 ,800 and change. And if you go to just pre the CPI report, which of course was the point at which small caps inflected relative to large caps, just as a for instance, within that index, if you simply broke the index into two categories or two cohorts, profitable Russell 2000 stocks and non-profitable stocks, there was an 18 percentage point spread between those with the profitable stocks handily outperforming that index itself and the non-profitable stocks not only underperforming but in negative territory.
12:42So that dividing line, you could do the same things with zombies versus non-zombies, with high interest coverage versus low interest coverage. And I think on a looking forward basis, maybe in part because of this rally that we've seen, I think you want to lean into the quality side of what's working, but maybe fade the lower quality side of what's working within those smaller cap indexes. Hey, Lizanne, it's Sam. So that sounds to me like you continue to lean into equal weighted. And again, an index, if you look at that, that's done half of what the S &P has. But the fact is, we're in the middle of bank earnings.
13:20It's been a very strong re-rating period for banks. There's an argument they could continue to re-rate. Energy, health care, you're starting to see some laggards across the energy space. J &J had good numbers out today, and at least some of these stocks are moving. You think about asset allocation every day. Can people follow this? Yes, but I think even within something like equal weight, it's not all created equal in terms of the stocks. I think this is an environment where you can't make monolithic decisions. whether it's at the index level, whether it's at the style box level, whether it's at the cap level, even at the sector level.
13:53I think factor based analysis and screening continues to be appropriate because both where leadership has resided and where it hasn't at the factor level has been much more consistent relative to leadership trends at the sector level or at the index level. So even within equal weight, I think you want to have that factor-oriented approach and stay up in quality. And that may seem like the ultimate duh statement. Why wouldn't investors always want to be in high-quality stocks? But, of course, there are times where it makes sense to go down the quality spectrum. That's where leverage to an upturn in the economy is or a major move on the part of the Fed to go from tightening to easing policy.
14:36I'm just not sure we're at that point in the cycle. So that's why I say I think you want to fade the lower quality, lean into the higher quality. And that's within small caps, even within the context of equal weight. Lizanne, it's Karen. Thanks so much for being on today. Question. I love the it's not a monolith. I sort of live by that. So when you talk about the Russell, I understand you don't want to make this sort of capital allocation to the monolith. But when you think about the quality there, are there particular industries that you favor now over others? I wouldn't say that's at the industry level.
15:13I'd say, again, it's at the factor level. So even though we're looking at a Fed that possibly is going to start easing policy in September, they're probably not inclined to do it aggressively. So to some degree, even in an easing cycle, we're in a higher for longer backdrop. And that is still, I think, suggestive of focusing on factors like high interest coverage. I already mentioned the profitability spread within small caps, the non-zombie type companies, strong return on equity, ample free cash flow, you know, those profitability metrics. I think that's the way to approach the market in this environment.
15:51And that can be applied across sectors, across industries. Within leadership sectors, there are great stocks and there are crappy stocks. And I think in this environment of lower correlations and wider dispersion, having gotten the return of the risk-free rate, ostensibly connecting fundamentals to stock prices again, leveling the playing field to some degree between active and passive, I think this is an environment where you continue to want to be more factor focused than sector or industry focused. Lizanne, great to see you. Hope to see you again soon. Lizanne Saunders of Schwab. Good points.
16:32Yeah, great points. I mean, listen, if one was worried about the crowding into these mega caps, right, and we can all agree big secular shift that's gone on in the last year and a half or so, if that's coming a little bit unwound right now, some of the air is coming out of that. And you've seen this crowding now into the small cap index. The Russell 2000 basically has the market cap of NVIDIA, right? So this thing has gone up 10 % in a straight line over the last week. It was unchanged a week and a half ago on the year, right? Look at the KRE, the small bank ETF. That's up 20 % in about two weeks or so.
17:03So if those trades come unwound, if, like, for instance, they start cutting because the economy starts slowing, don't you think regional banks are going to have a hard time? Don't you think the Russell 2000, which was punished in a higher for longer environment because their access to capital was harder, their cost of capital was higher, the whole thing, it just doesn't seem like chasing it here makes a lot of sense. And so money goes back into tech, which ultimately will at some point. I think these things could have a hard time, especially in a weakening economy. I read Lizanne's stuff voraciously.
17:33And one of the things she said, and we've talked about this, be careful what you wish for in the form of rate cuts because it may not be for the reasons you want. and actually maybe because Fed's trying to put out some fire. So, you know, I've said for a long time, if they can just sort of continue around this and just sort of slow and steady wins the race, that's probably the best case scenario. A Fed rate cut, somewhat counterintuitively, actually might be a negative thing for the market. And I just, I think the market also displayed some growth fears today. I mean, if you look across the resources space, if you look at also the places, we know Japan's got their own issues and what they need to do with the yen, but there's no disputing that there's an element of the yen trade, which is a carry trade.
18:09So you're starting to see some unwind there. You're starting to see some pain in places like copper that I think is Dr. Copper, has had a lot of speculation around it. But that was also part of today. Today expressed some fear of growth. And I think, you know, that's something to watch out for. Coming up, some after hours action in United Airlines and Discover Financial. We're diving into the numbers from those earnings next, plus the copper and a number of commodity trades lower today. The resource name is getting hit, too. Is this red hot trade now done? We will break it down.
18:42This is Fast Money with Melissa Lee right here on CNBC.
18:57Welcome back to Fast Money. We've got some after-hours earnings action. We start off with United Airlines. That stock turning positive in the last few minutes after posting an earnings beat and a revenue miss. CNBC's Contessa Brewer joins us now at the very latest. Hey, Contessa. Hi there, Melissa. Yeah, United's guidance for the third quarter disappointing. The street expected$3.44 in earnings per share for the third quarter, and instead United guided from$2.75 to$3.25 at the high end. Though the company says it's confident it will hit its full year guidance of$9 to$11 per share. The airline says August really is an inflection point, that the industry is seeing capacity growth decline by three points.
19:34It says it's going to see an acceleration of three factors that could give it an advantage. First, premium revenue in the quarter grew 8.5 percent over last year's second quarter. The second, basic economy revenue grew, are you ready for this, 38 percent year over year during the quarter. Third, market share among, and this is United's term for it, domestic road warriors increased during the quarter year over year. I don't know if it makes business travelers feel better to be called domestic road warriors. But anyhow, United says it will reduce its own capacity by an additional three points in the fourth quarter.
20:09You lose fewer seats. Maybe you can charge more for them. We'll see what happens. Melissa. Contessa, thank you. Contessa Brewer. Tim. Well, this is a bit of a relief on capacity, and this is what we've thought about for the entire airlines. To some extent, United priced in a better guide here. First of all, those numbers were fine. If you look across, they definitely beat across the board. They reaffirmed nine to 11 bucks a share. I think the guide was a little bit lower on the midpoint of EPS. But this this this capacity, this efficiency dynamics is very important. Remember, airlines have had a very big pullback after a very big run.
20:44So not a huge surprise. United bounced right off that 200 day. I think you've given a lot back. I mean, Delta and a difficult tape over the last couple of days has traded reasonably well after a 20 percent pullback. So I think you can follow this good news and believe in what they're telling you. You're smack in the middle of the range. It's been like$33.54 for the last two and a half, three years, number one. But, you know, Tim, if you're giving guidance full year of$9 to$11, you're not giving any guidance at all. I mean, you could drive a Boeing plane through that guidance. Oh, it's that far.
21:13No, I mean, that's a personal pet peeve. So if that's how wide your guidance is, you know what, you should say, you know what, folks, we don't have any clarity either. This is what we see for the next quarter. We don't really have a clue on full year. With that said, I mean, I think Delta, as Tim has said a number of times, is still best in breed. I think there might be some mojo in JetBlue off this sort of rounding bottom, as we discussed last night. All right. Meantime, Discover Financial higher after its earnings report. Steve Kovach joins us with the numbers. Hey, Steve. Hey, Mel. Yeah, shares of Discover Financial are up about 4 percent after hours after beats on both the top and bottom lines.
21:45Earnings per share coming in at$6.06, nearly double the$3.07 analysts were expecting. Revenue was$4.5 billion versus the$4.17 billion estimate. And the company reporting total loans ended the second quarter at$127.6 billion. That's up 8 % year over year. And just this morning, Carlisle and KKR agreed to acquire a more than$10 billion private student loan portfolio from Discover, which the company describes as a critical initiative. The conference call doesn't kick off until tomorrow at 8 a.m. Eastern, where investors will be listening for any commentary on the state of the American consumer. Again, shares moving higher on these results, Mel.
22:27All right, Steve, thank you. Steve Kovach. Karen, what did you make of this report? So a little bit noisy. That's why you had that huge earnings number, which was they were undoing the reserve release against those student loans. So taking that out, it was really about net interest margin and net interest income, both which were a beat. It was charge-offs, which were slightly lower. So those are two really good things, particularly for a company that is sort of right in the crosshairs of the consumer we're concerned about. Right. Right. So that was a bit of a surprise. So good for them. Then there is also will they do the merger?
Read the full transcript
23:03I mean, it seems to be progressing. We'll see. Interestingly, J.D. Vance does seem to be in the Lena Khan camp. Right. So I don't know. I mean, the merger makes sense to me. But who knows? Stranger things have happened. I mean, there had been that question because we were talking about how Bank of America and Citi, all of them commenting about the credit card exposure and how the consumer there is actually doing OK. But is it specific because they are sort of the higher income versus, yeah. Right. Both actually Bank of America and J.P. Morgan have the same expectation, about 3.4%. Here they're closer to 4, 8, 4, 9, different customers.
23:37So we have answers now about that lower end, lower credit quality, lower household income consumer. Yeah, well, we did hear some stuff from Citibank CFO last Friday that, you know, was calling into question some of the demand there and some of the stuff that they're seeing some of their retail partners. I'll just say this, you know, Wells Fargo, obviously, last Friday had a bit of a net interest income problem. The stock was down 6 percent over the next three trading days. It filled in the entire gap. So I think there's certain pockets of this trade where investors don't seem to be too worried.
24:07Maybe that's complacency. Again, this is, you know, if you're releasing reserves right now, you're a bank like that, you're probably not too worried in the near term. And we know that things can change very quickly as it relates to the consumer. Capital One, by the way, up 3 percent. Yep. And also the merger. So, yeah, well, I just I would point out that this might be a last hurrah for consumer credit, because then again, if you think about this, I'm not saying it's about to cave. I'm just saying if you think about this was one hundred thirty dollar stock before the Fed got aggressive in late twenty one, traded down to 80 bucks.
24:37And it's now traded well through that and is up almost 30 percent since mid June. Is this an environment where you're actually rewarding this company from the macro and the credit perspective? Obviously, company-specific you are and situation-specific you are. But if you think about DFS, at least historically, they would certainly be a place you'd be focused if you were worried about consumer credit. There's a lot more Fast Money to come. Here's what's coming up next. The copper trade is getting whiplash from red hot to ice cold. And now some of the space's top mining stocks need to dig themselves out of a hole.
25:10What today's pullback means for the future of the resource trade. After this, plus Roche soaring as the Swiss pharma giant looks to make waves in the weight loss trade. The skinny on the latest trial results and what it means for incumbents like Eli Lilly and Novo Nordisk. Next, you're watching Fast Money live from the NASDAQ market side in Times Square. Much more after this.
25:42Welcome back to Fast Money. Copper seeing a rough two months. The industrial metal down more than 15 percent from its May highs. And the recent rout being felt particularly in the copper miners today. Freeport-McMoran tech resources and southern copper all down sharply. Quite a different story, though, for gold, which touched another record earlier in the day. Though it did settle slightly lower. Guy, what do you make of this copper decline? I mean, we'll talk about it all the time. Copper is sort of an economic barometer without question. I guess to a certain extent it makes sense, although I wouldn't run too far from that.
26:12Gold's in a completely different dynamic, and I think it's going to continue to work in terms of what's going on. This ratcheted up rhetoric is very bullish for gold. I think what's happening in Japan is very bullish for gold, and central banks' continuing buy is very bullish for gold. And it's breaking out for the first time again in a while. And I think miners, gold miners specifically, will continue to work. Should we stay in gold, Tim, despite these records? I would stay in gold, and I'd stay in more gold, and I'd stay in more gold. There's nothing about the environment which includes more inflation possibly coming, but very much a case where I think we're going to have lower growth.
26:48We're going to have easier Fed policy. Very, very gold positive on top of the global central banks. Look, if everyone around the world is looking at the other person saying, we're not sure whether we're doing business with you or whether we trust you, gold's going higher. I think the dynamic with the dollar, look at that move that the dollar had today. It was a half a point. It's now probably, you know, not that far off of where it was. But weaker dollar is going to be also a very big deal for precious metals, industrial metals, and obviously core commodities. So, no, I think you've got a great opportunity in minors.
27:18All right. Coming up, Schwab on the slide. The brokerage firm down over 15 percent already this week as post-earnings woes continue. Is a relief in store or more pain to come? But first, huge obesity drug news out of Roche as new trial results, early phase trial results, show the company's latest treatment could have real promise. What it means for big players like Eli Lilly and Novo Nordisk right after this. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
27:56Welcome back to Fast Money. Two very different tales of the market today. The tech-heavy Nasdaq plunging nearly 3%. It's worst day since December 2022. The S &P down 1.5%. Meantime, the Dow jumped more than 240 points, setting new record highs and topping 41 ,000 for the first time ever. GE Vernova recording its worst day since spinning off from GE back in March. There are reports one of the company's wind turbine blades broke off off the coast of Martha's Vineyard this past weekend. And VF Corp surging today after announcing the sale of popular clothing brand Supreme to Oakley parent Essilor Luxottica for$1.5 billion.
28:32Meantime, U.S.-listed shares of Roche surging 7.5 % today after the company released upbeat clinical data on its oral GLP-1 weight loss drug. Participants losing 6.1 % more body weight than patients taking a placebo after four weeks on this drug. Those results sending shares of weight loss heavyweights Eli Lilly and Novo Nordisk each down nearly 4%. Other companies developing pills like Structure and Viking Therapeutics also sharply lower. Let's get more now with Mizuho Healthcare Sector Strategist Jared Holes, who is actually in the studio this time. As opposed to last time, which he had nothing to do, which he just said.
29:06He just didn't get me here. Anyway, please continue. Anyway, so this is one of the drugs that Roach acquired from Karmot. And the other drug, they had positive results back in May also for that obesity drug. So is Roach, does it have like a good chance now of getting something, you know, all the way through the pipeline? It's so hard to say. I mean, they're in the game. I mean, that was the purpose of acquiring the company for almost$3 billion last year. They're in the conversation. I think it's way too early. And this trial today, this oral obesity, six patients, I believe all of them were out of Australia.
29:40Wait, there were six patients? Six patients. In this study? So we're talking about... It should be, like, not even counted, I would think. Statistically insignificant. I didn't think it was going to have that major of an impact, but we've... And at least somebody from New Zealand as well. Exactly. Exactly. We've talked about all these trials that continue to hit. They're going to continue to come over the next year or two. And every time they seem to have a profound impact on the shares of Lilly, Novo, they bounce back almost every time. I think the same thing will happen here. And Viking and structure, I thought we're down way too much.
30:12I mean, you've Roche gaining $17 billion worth of value today, yet you've got companies that are a fraction of that that are moving lower, I felt like, if anything, they should be flat, maybe even up. I think the market will figure this out, if not tomorrow in the coming weeks, and those stocks will go back up. So I know it's a gigantic, huge market, but if you see results like this today that are so far away from actually turning into a product, do you expect to see others sort of drop out of the race? I don't think so. And only too big, too big. I mean, the market cap, you got two companies that have a combined market cap of almost$2 trillion, the market's begging these companies to be here, begging them.
30:54I mean, there's been nothing that's moved pharma stocks like this in the history of the industry, really. So for all those that are onlookers that have not made investments here that still might, I think the odds that they get into the game, whether it's a Merck, a J &J, et cetera, are pretty high. So by the way, go Browns. Great to have you here. And I don't know what these guys are saying. You know, sometimes you just can't get here. That same show, I happen to not be here, too, but we participated from afar, Jared. We did. And I think about, though, everything we're saying is reasons why you should be very worried, though, I think, about Lilly and about Novo.
31:28Because if ultimately everybody's going to get there, any hint of people getting in tells you that people are worried about these valuations and that the addressable market dynamic. Look, I'm long, Lilly. I'm long some other stuff, too. But I do think that this is a harbinger of price action. There's no question about it. And yes, they may be overreactions for now based upon six dudes in Australia. But I think this is something we should listen to. I think so, too. I think the thing that bothers me more about Lilly than anything else is that it's up so much this year. Right. If this were a stock that was up 15 or 20 percent, it's probably flat today.
32:03It's up 60. So I think you're seeing a correction. Obviously, the market orientation would have probably sent Lilly and Novo down or they would have been flat today anyway. I'm not super worried about it, but, yeah, I mean, the competition is coming. It's very significant across pharma, across biotech, so there are going to be more of these. But the puck moves in this game, right? Oh, nice. And I hate sports because I can't really follow through beyond the puck moves. But basically, they're going to come out to market with an oral GLP-1. Fantastic. But the next goal is going to be a GLP-1 or a weight loss drug that doesn't deteriorate muscle mass and so on.
32:39And so if Eli, Lillian, Nova are still ahead of the game in those races, then they will maintain their lead. Do I hear about a hat trick possibly? No, I don't even know what that is. I'm not going to try that. I think that's right, too. I mean, I think Lillian, Nova are years ahead. They've got the most money. So they're the most well capitalized. They can continue to innovate probably better, faster than any of the other players. And they're going to have different modalities, different drugs that they bring to market probably before a Roche, before a Pfizer. So I'm not incredibly worried about the competition.
33:09But, yeah, like any time you have two companies with this sort of lead and there's any sort of conversation at all that others could kind of penetrate that market, you're going to see share weakness. And part of this is a rotation, right? I mean, just into the rotation that's going on in the broader markets in total, right? Sure. Yeah. Yeah. I mean, today the Pfizer is turning around. What? That's crazy. Right. You're Pfizer. I know. You guys. The 30 handle for the first time since 2023. Right. Right. Pfizer up a lot. Bristol up almost 5 percent at one point today. So you're getting you're getting a value and you're getting an underperformer rotation, which is kind of synonymous at this point, concurrent with this news.
33:48It kind of all set up for these for Lillian Nova to underperform today. I don't really think I doubt it less. OK, Jared, great to see you in person. Thank you. Hope to see you in person again. We goodbye the guest. I'm pretending he's not here. But I will say that, you know, we've had him on a number of times. Remember when Viking Therapeutics, I think they announced the news during our show or the day of one of our shows, stock showed up almost$100. It has been cut in half since. And we talked about it then, probably ahead of itself. It's going to give you an opportunity now. I don't think we'll go down 50%.
34:17But this, to me, is a name that's in the crosshairs of a lot of big cap pharma. I mean, you don't buy things for takeout, but this is one you want to look at for that. How are you feeling about your Pfizer? I agree. Better. I think it's the best thing about Pfizer right now is the chart. The best thing is that it's been basing. There's been a lot of news and a lot of disappointment and a lot, frankly, a lack of catalysts. But again, and I would look at J &J, which is another name that I'm long. And, you know, they had decent, if not solid numbers today. They talked about five percent growth on the top line.
34:48That's that's very solid with an innovative med business that's actually growing better. Their med tech was a little weaker. They've got this talc overhang. But Bristol Myers, as Jared talked about it, he's gone. But, I mean, the PFE, the J &J, these are stories that I do think are part of our first part of this show. I mean, people want to own these stocks. They're not difficult valuations, and I think they go higher. And Talcata has to be at the end of the month with the vote. That's right. They've got to vote the plaintiffs on the 26th. All right, coming up, Schwab shares sinking. The brokerage stock trading at close to the lows of the year.
35:18What is behind today's move, and is there more pain to come? And Netflix earnings kickoff. Big tech reports tomorrow what the options market is expecting. Ahead of those results, more Fast Money in two.
35:35Welcome back to Fast Money. Shares of Charles Schwab tumbling for a second straight day after TD Cowan downgraded the stock on the back of yesterday's earnings. The stock now down nearly 16 percent this week. Analysts pointing to what they call poor execution in earnings power as reasons for the downgrade. Schwab yesterday reported a drop in interest income and a decline in profit. shares now trading near their lowest levels of the year. Karen, what do you make of this drop? Well, I think I don't I want to I don't want to say it's overdone, but I think it's a pretty, pretty big reaction to what actually is not a great problem, though.
36:10That's the thing. Right. They're going to sort of shrink their way out of it by getting deposits off balance sheet. I never love shrink the way out of anything. No. Maybe it's the right thing to do here. But it's funny. I don't know. You guys are snickering. No, I... Why did you even say you guys? I never love it when you shrink your way out of it and you laugh. It's never a strategy, by the way. But it's not a strategy. It's not a growth strategy. It's a... There's two things. Her point about shrinking is that essentially when you think about this company, I think net interest or interest income is their biggest revenue line, right?
36:47So if you talk about shrinking the bank and then they're also talking about... Listen, you would have thought when interest rates were going higher, right, it took out Silicon Valley. It took out. They were in the penalty box a little bit for some of the same reasons. Their portfolio of treasuries, that mark-to-market loss was not particularly great. And losing deposit. Correct. And so now if you're going to shrink it, okay, and also they were talking about buying some of that high-cost debt, and that would be capital that they might have used for buybacks. Some of their debt traded down a little bit today.
37:14Yeah. What was the problem with shrinking the business? Why? Because I don't have an issue with what they're trying to do. See, that's Primrose Path stuff right there. I'll take you off. Guy, do you think down 20 % in two days was overdone? It's a lot. It's overdone. No? Not necessarily. I mean, they were in the crosshairs, as Dan just said, getting it back there. In Silicon Valley Bank, a lot of those problems, obviously, with what happened in the market were sort of glossed over. I don't think they necessarily went away. And I think Charles Schwab is one of those names. It's a really important market sentiment indicator.
37:50And if it continues to trade lower, that's something that people might start focusing on. Breaking news here on Senator Bob Menendez. Emily Wilkins has got the latest. Emily. Hey, Melissa. Well, NBC is now. Hey, Melissa. NBC is now reporting that Senator Bob Menendez has been telling allies that he will resign and step down from his Senate seat. This, of course, comes after yesterday when he was found guilty on numerous counts for things including bribery and acting as a foreign agent. Menendez has been called on by 44 Democrats to step down at this point, especially with that guilty conviction yesterday.
38:26And now we can report that he has been telling allies that he will go ahead and step down. And, of course, this opens up for the potential election. He wasn't the nominee. There is a different Democratic nominee in Andy Kim. but he was still planning on running as an independent, and it seems like that will no longer be the case. Melissa? Emily, thank you. Emily Wilkins. Coming up, Netflix kicks off tech earnings season tomorrow. What the market is predicting from the results and a way to play it using options. And here's a sneak peek at the Kramer cam. Jim is chatting exclusively with the First Horizon CEO.
38:59Catch the full interview, top of the hour on Mad Money. Meantime, more Fast Money in two.
39:09Welcome back to Fast Money. The countdown to Netflix earnings is on. The streaming giant headlining the after hours action tomorrow as shares try to break back to all time highs. The options market is betting on a marquee move when this name reports. Mike Coe has the action. Hey, Mike. Hi there. Right now, the options market, Netflix implying a move of just over 8 percent by the end of the week after they report earnings. And as big a move as that is, that's less than the nine and a half percent that the company has averaged over the last eight reported quarters. And the trade that stuck out to me was a purchase of a couple hundred of the July 700 calls.
39:41Buyer paid$9 a contract for that. And the quick point I would make is that's an interesting level for two reasons. Number one, that is approximately the implied move to the upside. And number two, 700 is also that all-time high that you just referred to. And the stock has been a little bit weak since it bounced off of that level. So if you are inclined to make a bullish bet, I think buying those calls is a better bet than reaching out and buying the stock right here. And taking a look at the last eight reported quarters, it has been a winning bet as well. Even though only five of those have been winners, you actually would have been better off buying options like these, costing a little less than 1.4 % of the current stock price than going out and buying the stock itself.
40:16You know, it's interesting. In that last quarter, remember the stock gap down about 10%. There was two things in that. So the subscriber growth was less than expected. And they also signaled that they were going to stop posting subscriber numbers. And, you know, since then, the stock has just ripped, right? It had that gap. And it didn't stay down there for too long. And so to me, I just think where it is right now, probably not a great buy. I like what Mike is suggesting calls to find a risk. Well, I had sold some calls a few days in. All the days are blending together just because I do think that run has been so big.
40:46They're not great at sort of the guidance sort of thing, right? Forecasting is not their thing. Yes. No. So you absolutely need to listen to the call. It's super important on this one. Yeah. Yeah. I think this falls under some of the mega cap tech concentration where you've had a big winner. We all know the stock has tripled over the last couple of years. The valuation is very different than it started. But it's not a case of a mega cap tech stock that we're really questioning whether they you know, it's a question of what's the multiple you want to pay for a company that's so far out ahead of the others guy.
41:13I know you're a big Bridgerton fan and queen of tears and whatnot. So, you know, you tell me. But I think engagement is also part of what we're looking at. He knows not of what you speak. You know, you say that you throw it out there. I don't know Bridgerton. I've not watched it from what I'm told. It's like soft pornography, which I do not advocate. But clearly you're familiar with it, Tim. So maybe you're just sort of, once again, you're sort of just throwing, projecting it over to me. Just throwing it out there. Netflix trade, if you will. The implied move gets you right back to those prior highs we saw back in 2021 and basically a couple weeks ago.
41:47Karen was smart to sell calls. I think what you're hoping for is a move to the downside where you get it sort of south of$600 and then reload again, Melms. Mike Coe, thank you. Up next, Final Trades.
42:10Time for the final trade. Let's go around the horn. Tim Seymour. Part of this broadening, I think it's Boeing. I think it's not just a fence, but I think it's Boeing and a lot of the issues that at least are out there. Karen Feinerman. Yes. Sort of along those same lines, talking about the rotation. We were just talking about Pfizer. And if anyone is looking for a stock with a low P.E. multiple and a very high yield and still some good product, then yes, Pfizer is a decent thing to go. Dan, Nathan. Yeah, KRE. That's a small cap bank index. I just think it's a little overdone, 18 % in one week.
42:43Guy. Apparently, if you watch Bridgerton, Mel, you do not have to shrink your way out of things, but that's just sort of anecdotal. Tim filled me in on that earlier in the show. Lockheed Martin continues to go higher here. Hugh, that's all I can say. Thanks for watching Fast Money. See you back here tomorrow at 5 for more Fast Mad Money with Jim Kramer starts right now.
43:06All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.
43:40To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.
From the publisher
Shares of ASML, Taiwan Semi and Nvidia sinking today as the SMH semiconductor ETF sees its worst day in over four years. Will rising geopolitical tensions mark the end of this recently red-hot trade? Plus positive trial results on Roche’s weight-loss pill sending those shares higher and those of competitors lower. We dive in on the latest developments in the GLP race.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
